COVID-19 infection. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: In order to minimize any bias between groups as a general policy, all patients will only receive lopinavir/retonavir (Kaletra®) and corticosteroids as their treatme
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: >18 yrs old PCR confirmation of COVID-19 Severe or critical diseases as: respiratory rate>30 breaths/second, oxygen saturation50%, partial pressure of oxygen/Fraction of inspired oxygen <300 mmHg and/or any individual with respiratory failure, septic shock, and/or multiple organ dysfunction
Exclusion criteria
Exclusion criteria: Pregnancy G6PD deficiency Severe renal failure (defined as glomerular filtration rate<15 mL/min/1.3m2) History of allergic reaction to drug Patients on serotonergic psychiatric drugs (including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake Inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors), dapsone and different hydroxylamine Organ transplantation recipients Not consenting to enter study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Death. Timepoint: 2 weeks after intervention. Method of measurement: follow-up visit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Partial pressure of oxygen/Fraction of inspired oxygen. Timepoint: first day of hospital admission, and 1, 3, and 5 days after administration. Method of measurement: By measuring arterial blood gas.;Length of hospital stay. Timepoint: Daily until discharge. Method of measurement: Daily follow-up visitation.;ICU admission rate. Timepoint: ?Daily until the end of hospitalization. Method of measurement: Daily follow-up visitation.;In-hospital complications rates. Timepoint: Daily until the end of hospitalization. Method of measurement: Daily follow-up visitation.;White blood cell count/leukopenia. Timepoint: first day of hospital admission, and 1, 3, and 5 days after administration. Method of measurement: By blood test.;C-reactive protein levels. Timepoint: first day of hospital admission, and 1, 3, and 5 days after administration. Method of measurement: By blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactJamshid Roozbeh
Shiraz University of Medical Sciences
Outcome results
None listed